← FDA DRUG APPROVALS

FDA ANDA · ANDA075039

OXYBUTYNIN CHLORIDE

Sponsor: CHARTWELL RX

APPLICATION
ANDA075039
TYPE
ANDA
ORIGINAL APPROVAL
1999-01-29
LATEST ACTION
2006-10-26
ROUTE
ORAL
DOSAGE FORM
SYRUP
MARKETING STATUS
Prescription

Products

OXYBUTYNIN CHLORIDEPrescription
OXYBUTYNIN CHLORIDE 5MG/5ML · SYRUP · ORAL

Approval history

2006-10-26Labeling · Supplement 4AP
2002-08-13Manufacturing (CMC) · Supplement 1AP
1999-01-29OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →